Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/11/20
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine CandidateGlobeNewsWire • 08/07/20
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19GlobeNewsWire • 07/22/20
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ OptionGlobeNewsWire • 07/16/20
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 07/14/20
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 07/13/20
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID™GlobeNewsWire • 07/13/20
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™GlobeNewsWire • 07/09/20
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine CandidateGlobeNewsWire • 06/30/20
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19GlobeNewsWire • 06/29/20
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis BGlobeNewsWire • 06/22/20
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19GlobeNewsWire • 06/01/20
Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?Zacks Investment Research • 05/15/20